Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
November 07 2022 - 8:00AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company today
announced a poster presentation highlighting the potential of the
Company’s human neoantigen T-cell receptor platform (hunTR) to
expand its TCR Library. The data will be presented at the Society
for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston,
Massachusetts from November 8-12, 2022.
“We are excited to present data demonstrating
the ability of our proprietary hunTR platform to rapidly identify
and validate neoantigen-reactive TCRs,” commented Drew Deniger,
Ph.D., Vice President, Research & Development. “By leveraging
hunTR, our aim is to efficiently expand our TCR-T Library Phase 1/2
program with new, proprietary TCRs. This will enable us to broaden
the pool of eligible patients who could benefit from our non-viral
TCR-T cell therapies. We look forward to expanding our application
of hunTR™ for additional shared KRAS, TP53, and EGFR mutations and
rapidly take novel TCR candidates from the lab through to clinical
translation.”
Details for the presentation are as follows:
Title: hunTR™: a hyperplex platform for the
discovery of neoantigen-reactive T-cell
receptorsPresenter: Guowei Gu, PhD, PharmD,
Sr. Scientist, Translational Sciences, Alaunos
TherapeuticsDate/Time: Thursday, November 10,
2022, 10:40am – 1:10pm ET and 7:30pm – 9:00 pm
ETLocation: Boston Convention &
Exhibition Center, Hall CAbstract
Number: 227
hunTR is a high-throughput screening process
that uses state-of-the-art bioinformatics and next generation
sequencing to interrogate and deconvolute thousands of single T
cells simultaneously. In the study, Alaunos evaluated ~525,000
TCR+HLA+neoantigen combinations in nine patients across colorectal,
endometrial and breast cancers. All patients screened had at least
one detectable neoantigen-reactive TCR, including one shared
KRAS-Q61H mutation and 21 personal mutations. Of these, 78% were
restricted by HLA Class II while 22% were restricted by HLA Class
I. A median reactive hit rate of 13% was achieved per patient with
an average of three unique neoantigen specificities. In subsequent
patients screened only for KRAS mutations, multiple patients had
TCRs reactive to KRAS-G12V, further demonstrating the ability of
hunTR to discover exclusively owned hotspot mutation-reactive TCRs
that could be added to the clinical library. The Company plans to
continue to expand the application of hunTR to screen for
additional shared KRAS, TP53, and EGFR mutations to rapidly advance
new TCR library candidates from the lab through to clinical
translation. In addition, hunTR may be suitable for personalized
TCR-T therapies, enabling mutation-targeted cell therapy for most
solid tumor cancers.
About Alaunos
TherapeuticsAlaunos is a clinical-stage oncology-focused
cell therapy company, focused on developing T-cell receptor (TCR)
therapies based on its proprietary, non-viral Sleeping Beauty gene
transfer technology and its TCR library targeting shared
tumor-specific hotspot mutations in key oncogenic genes including
KRAS, TP53 and EGFR. The Company has a clinical and strategic
collaboration with the National Cancer Institute. For more
information, please visit www.alaunos.com.
Forward-Looking Statements
Disclaimer This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as “may,” “will,” “could,” “expects,” “plans,”
“anticipates,” “believes” or other words or terms of similar
meaning. These statements include, but are not limited to,
statements regarding the Company's business and strategic plans,
the anticipated outcome of preclinical and clinical studies by the
Company or its third-party collaborators, the Company’s
manufacturing capabilities and the timing of the Company's research
and development programs, including the expected timeline for
enrolling and dosing patients and the timing and forums for
announcing data from the Company's clinical trials. Although the
management team of Alaunos believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Alaunos,
that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include, among other things, changes in the Company’s
operating plans that may impact its cash expenditures; the
uncertainties inherent in research and development, future clinical
data and analysis, including whether any of Alaunos’ product
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for
which indication; the strength and enforceability of Alaunos’
intellectual property rights; and competition from other
pharmaceutical and biotechnology companies as well as risk factors
discussed or identified in the public filings with the Securities
and Exchange Commission made by Alaunos, including those risks and
uncertainties listed in the most recent periodic report filed by
Alaunos with the Securities and Exchange Commission. Alaunos is
providing this information as of the date of this press release,
and Alaunos does not undertake any obligation to update or revise
the information contained in this press release whether as a result
of new information, future events, or any other reason.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2024 to May 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From May 2023 to May 2024